Przegląd Gastroenterologiczny

Abstract

1/2019 vol. 14
Original paper

Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis

Gastroenterology Rev 2019; 14 (1): 48–54
Online publish date: 2019/03/12
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

Interleukin-35 (IL-35) is a newly defined potent anti-inflammatory cytokine that is predominantly produced by regulatory T cells, and pentraxin-3 belongs to the acute-phase proteins.

Aim

To measure the serum IL-35 and pentraxin-3 levels in the early phase of mild acute pancreatitis (AP).

Material and methods

Eighty-three patients with mild AP and 30 healthy controls were included in the study. The serum levels of IL-35 and pentraxin-3 were measured by enzyme-linked immunosorbent assay upon admission and at the 48th hour after diagnosis.

Results

The mean value of serum IL-35 levels in patients with mild acute pancreatitis at admission was 5.91 ng/ml (4.21–7.90) and was significantly lower than those in healthy controls (25.53 ng/ml (12.79–54.73, p < 0.001)) and 48-hour value were (6.79 ng/ml (4.42–9.62) (p = 0.015)). The mean value of serum pentraxin-3 levels in patients at the time of admission was 6.75 ng/ml (4.42–9.62) and there was no significant difference from healthy controls, at 7.64 ng/ml (6.58–8.62, p > 0.05). Also there was no significant difference between the mean value at admission and the mean value at 48-hour, 6.75 ng/ml (4.74–9.06, p > 0.05).

Conclusions

Interleukin-35 can be used in diagnosis and follow-up in patients with mild AP.

Share
without publication fees